Richmond Pharmacology celebrates 5th year in clinical trials!

Posted:
25
August 2005

We have great pleasure in announcing that we are officially operating in our 5th year of clinical trials. Richmond Pharmacology was formed in August 2001, since when we have grown to become the largest Phase I–IV Clinical Trials Centre in the UK, with a well earned reputation for specialties such as QTc Studies and Bridging Studies, and more recently Patient Studies across numerous therapeutic areas.The three founding directors, Dr Ulrike Lorch, Dr Radivoj Arezina and Dr Jörg Täubel have used their combined clinical trials experience of 45 years to develop a CRO and SMO that has embraced innovation and partnered NHS and university medical schools to deliver Phase I to IV studies.Dr Ulrike Lorch, Medical Director, added: “Our fundamental objective was to base all our clinical trials within NHS Teaching Hospitals to tap into the advantages of first rate safety measures and on-site therapeutic expertise, allowing us to work hand in hand with our clinical colleagues whenever required. We are now the UK's only CRO to be based within two such hospitals.”

Dr  Jörg Täubel

Dr Jörg Täubel MD MFPM, Managing Director of Richmond Pharmacology

Dr Jörg Täubel, Managing Director commented: “When we launched Richmond, our plan was always to create a clinically excellent Integrated Trials Centre, capable of delivering pharmacology and patient studies in combination or independently of one another.“We are proud of our new Phase I facilities at Mayday University Hospital. The Unit has been purpose built and boasts modern, spacious wards, lounges and internet rooms. To move our second unit to this acute 3 star 780 bed NHS hospital represents the culmination of the best of in-patient facilities, technology and methodology. Richmond Pharmacology has a combined 100 beds based in St George's Hospital and Mayday University Hospital, and has grown to be able to deliver any type of pharmacology and patient study across a multiplicity of therapeutic areas.“It is fascinating to be based within a learning environment which influences our company's culture.”Since 2001, Richmond have been hosting annual seminars with renowned opinion leaders to tackle the most topical issues in Early Phase research, including Electronic Data Capture, Bridging Studies and QTc studies. This year's 4th annual seminar – “Early Phase Trials Integration – Introducing Evolution in Clinical Trials” – explores the changing context within which clinical trials are being conducted, and considers the advantages of conducting early Phase trials within a hospital environment (for more information call Keith Berelowitz on 020 86645200).

Volunteers relaxing in our new facilities

Volunteers relaxing in our new facilities

We have also broadened our service portfolio with the creation of in-house data management services using a fully validated platform based on Oracle Clinical Version 4.5. In recent studies we have routinely locked clean databases within 4 weeks from the last patient visit.Dr Radivoj Arezina commented “We have always appreciated the need for comprehensive good quality data produced in the shortest possible time. Indeed in many of our recent studies data entry and management were done on an ongoing basis throughout the trial. Our team has proved to be flexible in their approach and producing excellent quality to tight deadlines.”Richmond Pharmacology would like to extend our thanks to our clients, partners and suppliers in working with us during this exciting period of growth. Furthermore, we would like to express our appreciation to our excellent staff. Their standards of commitment and expertise across our clinical and all support functions have enabled Richmond to successfully grow and diversify. We continue to recruit and retain the best professionals in every area of the business.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more